Vol.

No.

October 08, 2021Oct 08, 2021

Free

DOWNLOAD THE PDF

Pancreatic cysts are common and usually benign—except those that turn deadly An NCI trial compares surveillance regimens

Cover Story

Free

Pancreatic cysts are common and usually benign—except those that turn deadly

An NCI trial compares surveillance regimens

By Paul Goldberg

An argument can be made that only a government research agency like NCI has the capacity to answer questions about monitoring pancreatic cysts—and how some of them turn malignant.

Conversation with The Cancer Letter Free

David Weinberg: Only NCI has the capacity to answer public health question on managing pancreatic cysts

By Paul Goldberg

Conversation with The Cancer Letter Free

Peter O’Dwyer and Mitch Schnall on the challenges of running screening and prevention trials

By Paul Goldberg

Free

Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?

By Alice Tracey

Free Guest Editorial

Vinay Prasad’s Nazi analogy is imbecilic, ignorant, and dangerous

By Arthur L. Caplan

Free

Francis Collins steps down after 12 years as NIH director

By Matthew Bin Han Ong

Free Obituary

Thomas A. Waldmann, renowned immunologist, dies at 91

By NCI Staff

Free In the Archives

The Emil J Freireich archive: tributes, primary sources, and videos

In Brief

SU2C Dream Team takes on colorectal cancer disparities

Michael Diaz named president, managing physician of Florida Cancer Specialists and Research Institute

Mount Sinai researchers receive $4M in grant awards for junior scientists

$1M gift furthers UNC research on breast cancer disparities, barriers to high-quality care

Clinical Roundup

One in seven patients missed cancer surgery during COVID-19 lockdowns

Rates of HCC are rising in rural areas while slowing in urban areas

NASEM publishes guidance for campus climate surveys measuring sexual harassment

Chronic stress may impact treatment completion, survival outcomes in patients with breast cancer

UAMS and Mayo Clinic researchers advance PROTAC technology for targeted molecular therapy

NCI to study Anktiva + Keytruda as a chemo-free NSCLC therapy in 700-site Lung-MAP clinical trial

Gel enhances CAR T benefits in brains surgically treated for glioblastoma

NRG Oncology launches FORTE, a colorectal cancer prevention clinical trial

Drugs & Targets

FDA approves Tecartus for relapsed or refractory B-cell precursor ALL

FDA recognizes MSK database of molecular tumor marker information

EMA validates relatlimab + nivolumab application for advanced melanoma

MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program

NEXT Oncology expands phase I program with VCS partnership

NCI Trials

NCI Trials for Oct. 2021

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 49 | Issue 44 - December 01, 2023

Pancreatic cysts are common and usually benign—except those that turn deadly

David Weinberg: Only NCI has the capacity to answer public health question on managing pancreatic cysts

Peter O’Dwyer and Mitch Schnall on the challenges of running screening and prevention trials

Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?

Vinay Prasad’s Nazi analogy is imbecilic, ignorant, and dangerous

Francis Collins steps down after 12 years as NIH director

Thomas A. Waldmann, renowned immunologist, dies at 91

The Emil J Freireich archive: tributes, primary sources, and videos

In Brief

SU2C Dream Team takes on colorectal cancer disparities

Michael Diaz named president, managing physician of Florida Cancer Specialists and Research Institute

Mount Sinai researchers receive $4M in grant awards for junior scientists

$1M gift furthers UNC research on breast cancer disparities, barriers to high-quality care

Clinical Roundup

One in seven patients missed cancer surgery during COVID-19 lockdowns

Rates of HCC are rising in rural areas while slowing in urban areas

NASEM publishes guidance for campus climate surveys measuring sexual harassment

Chronic stress may impact treatment completion, survival outcomes in patients with breast cancer

UAMS and Mayo Clinic researchers advance PROTAC technology for targeted molecular therapy

NCI to study Anktiva + Keytruda as a chemo-free NSCLC therapy in 700-site Lung-MAP clinical trial

Gel enhances CAR T benefits in brains surgically treated for glioblastoma

NRG Oncology launches FORTE, a colorectal cancer prevention clinical trial

Drugs & Targets

FDA approves Tecartus for relapsed or refractory B-cell precursor ALL

FDA recognizes MSK database of molecular tumor marker information

EMA validates relatlimab + nivolumab application for advanced melanoma

MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program

NEXT Oncology expands phase I program with VCS partnership

NCI Trials

NCI Trials for Oct. 2021

Recent Issues

Renew today!

Subscriber content

Login